Medpace Holdings, Inc. Share Price

Equities

MEDP

US58506Q1094

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 15/06/2024 am IST 5-day change 1st Jan Change
393.9 USD -0.05% Intraday chart for Medpace Holdings, Inc. -1.81% +28.51%
Sales 2024 * 216.99Cr 18TCr Sales 2025 * 252.15Cr 21TCr Capitalization 1.22TCr 1,01700Cr
Net income 2024 * 36Cr 3.01TCr Net income 2025 * 42Cr 3.52TCr EV / Sales 2024 * 5.29 x
Net cash position 2024 * 69Cr 5.79TCr Net cash position 2025 * 95Cr 7.9TCr EV / Sales 2025 * 4.45 x
P/E ratio 2024 *
35 x
P/E ratio 2025 *
30 x
Employees 5,800
Yield 2024 *
-
Yield 2025 *
-
Free-Float 82.14%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.05%
1 week-1.81%
Current month+1.96%
1 month-1.16%
3 months-2.64%
6 months+32.15%
Current year+28.51%
More quotes
1 week
386.43
Extreme 386.425
409.00
1 month
379.15
Extreme 379.15
410.05
Current year
277.72
Extreme 277.72
421.00
1 year
216.87
Extreme 216.87
421.00
3 years
126.95
Extreme 126.945
421.00
5 years
55.50
Extreme 55.5
421.00
10 years
21.76
Extreme 21.76
421.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 67 01/92/01
Director of Finance/CFO 49 01/18/01
President 49 01/07/01
Members of the board TitleAgeSince
Director/Board Member 72 13/18/13
Chief Executive Officer 67 01/92/01
Director/Board Member 64 13/18/13
More insiders
Date Price Change Volume
14/24/14 393.9 -0.05% 128,196
13/24/13 394.1 -2.39% 200,163
12/24/12 403.7 +1.65% 201,271
11/24/11 397.2 -2.10% 159,982
10/24/10 405.7 +1.12% 140,833

Delayed Quote Nasdaq, June 15, 2024 at 01:30 am IST

More quotes
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
393.9 USD
Average target price
428.5 USD
Spread / Average Target
+8.78%
Consensus